La cadena de opciones muestra datos clave de las opciones de acciones de Webuy Global a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Webuy Global..

Webuy Global (NASDAQ:WBUY) Bolsa, Cadena de Opciones

Webuy Global Ltd is an emerging Southeast Asian (SEA) community-oriented e-commerce retailer (Community e-Commerce Retailer) with a focus on grocery and travel. Community e-commerce is a deepened extension form of e-commerce, where social media users with mutual interest and like-minded behavior are connected, forming a community group within a network through an online medium. Its mission is to make social shopping a new lifestyle for consumers and to empower consumers' purchases with an efficient, cost-saving purchasing model. The company is also engaged in selling packaged tours to its customers. The majority of revenue is derived from the sales of groceries through its online platform. Its geographic areas are Singapore, Indonesia, and Malaysia.

Stock,Market,Graph,Trading,Analysis,Investment,Financial,,Stock,Exchange,Financial

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ABSI

ALLT

ALUR

ASNS

AXDX

DBVT

DEVS

FNGR

GRAL

LRHC

LUCY

PLRZ

UBER

WBUY

XHLD

XTKG

Las acciones de Everus Construction Group suben un 14,7 % tras superar expectativas de ganancias y ventas en el primer trimestre.

Acciones de Everus Construction (ECG) se disparan un 15%; Aquí están 20 acciones que se mueven en premercado

WEBUY GLOBAL LTD. - Class A Ordinary Shares

Webuy Global Ltd

Webuy Global Ltd Ordinary Shares - Class A

RBC Capital analyst Matthew Hedberg maintains Cloudflare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NET#NYSE">NET</a>) with a Outperform and raises the price target from $210 to $228.

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Cloudflare, Raises Price Target to $228

<a href="https://www.bloomberg.com/news/articles/2025-08-01/saudi-oil-rigs-slump-to-lowest-in-20-years-outpaced-by-gas">https://www.bloomberg.com/news/articles/2025-08-01/saudi-oil-rigs-slump-to-lowest-in-20-years-outpaced-by-gas</a>

Macro Notification

General

'Saudi Oil Rigs Slump to Lowest in 20 Years, Outpaced by Gas'- Bloomberg

UBS analyst David Vogt maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Neutral and raises the price target from $210 to $220.

AAPL

UBS Maintains Neutral on Apple, Raises Price Target to $220

RBC Capital analyst Greg Pardy maintains Cenovus Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CVE#TSX">CVE</a>) with a Outperform and raises the price target from C$25 to C$26.

TSX:CVE

RBC Capital Maintains Outperform on Cenovus Energy, Raises Price Target to C$26

<a href="https://www.marijuanamoment.net/trump-privately-committed-to-reschedule-marijuana-multiple-times-since-taking-office-ceo-says/" title="https://www.marijuanamoment.net/trump-privately-committed-to-reschedule-marijuana-multiple-times-since-taking-office-ceo-says/">https://www.marijuanamoment.net/trump-privately-committed-to-reschedule-marijuana-multiple-times-since-taking-office-ceo-says/</a>

Biotech

Politics

AKAN

CRON

GRWG

IMCC

MAPS

MSOS

SNDL

TLRY

"Trump Privately Committed To Reschedule Marijuana 'Multiple Times' Since Taking Office, CEO Says" - Marijuana Moment

WIIM

BEN stock has given up its prior loss. Franklin Resources shares were trading lower after the company reported a Q3 revenue miss.

Shares of Novavax Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) reported disappointing second-quarter financial results and cut its full-year forecast.
What To Know: Moderna announced on Friday a significant second-quarter loss of $2.12 per share, <a href="https://www.benzinga.com/markets/earnings/25/08/46791309/modernas-key-patent-win-overshadowed-by-gloomy-outlook">substantially missing</a> analyst expectations of a 93 cent per share loss. 
The company also lowered its 2025 revenue guidance to a range of $1.8 billion to $2.2 billion, a $300 million reduction from the previous forecast&#8217;s midpoint. The weaker outlook was attributed to a continued decline in demand for its COVID-19 vaccine, with sales falling 41% year-over-year to $211 million.
The <a href="https://www.benzinga.com/pressreleases/25/08/ac46789412/moderna-reports-second-quarter-2025-financial-results-and-provides-business-updates">negative report</a> from Moderna has cast a pall over the sector, shifting investor focus to Novavax&#8217;s own upcoming earnings report. Novavax is scheduled to release its quarterly results before the market opens on Wednesday, August 6. 
Current Wall Street estimates <a href="https://www.benzinga.com/quote/NVAX/earnings">project</a> the company will post a loss of 6 cents per share on quarterly revenue of approximately $156.30 million.
While Novavax <a href="https://www.benzinga.com/news/health-care/25/07/46605800/novavax-shares-promising-results-for-bird-flu-vaccine-tested-in-primates">recently shared</a> positive preclinical data for its H5N1 bird flu vaccine candidate, the market&#8217;s immediate concern appears centered on the financial viability of the COVID-19 market. 
Investors will be closely watching Novavax&#8217;s report next week for signs of revenue stability and updates on its pipeline to gauge if it can avoid the headwinds currently facing Moderna.
Benzinga Edge Rankings: Based on <a href="http://benzinga.grsm.io/register174">Benzinga Edge</a> stock rankings, which evaluate stocks on key metrics, Novavax currently exhibits a bearish technical profile. The stock shows very weak momentum with a score of just 11.86. 
This is further corroborated by negative price trend signals across the short, medium, and long-term outlooks. The company&#8217;s Value score sits at a neutral 47.07, suggesting it is not considered significantly over or undervalued at its current price.
Price Action: According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NVAX shares are trading lower by 3.23% to $6.43 Friday morning. The stock has a 52-week high of $15.22 and a 52-week low of $5.01.
Read Also: <a href="https://www.benzinga.com/news/legal/25/07/46578238/clorox-claims-cognizant-handed-credentials-to-hacker-ignored-security-protocols">Clorox Claims Cognizant Handed Credentials To Hacker, Ignored Security Protocols</a>
<h2 class="wp-block-heading">How To Buy NVAX Stock</h2>
By now you're likely curious about how to participate in the market for Novavax &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy &#8220;fractional shares,&#8221; which allows you to own portions of stock without buying an entire share.
In the case of Novavax, which is trading at $6.43 as of publishing time, $100 would buy you 15.55 shares of stock.
If you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to &#8220;go short&#8221; a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Image: Shutterstock

MRNA

NVAX

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

RBC Capital analyst Greg Pardy maintains Cenovus Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) with a Outperform and raises the price target from $25 to $26.

RBC Capital Maintains Outperform on Cenovus Energy, Raises Price Target to $26

The Board of Directors of Illinois Tool Works Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITW#NYSE">ITW</a>) authorized a seven percent increase to the dividend payout to shareholders, representing a quarterly increase of $0.11 per share – or $0.44 per share annually – versus the current dividend rate. The Board also declared a dividend on the company's common stock of $1.61 per share for the third quarter of 2025. The dividend equates to $6.44 per share on a full-year basis. The dividend will be paid on October 10, 2025 to shareholders of record as of September 30, 2025.

Dividends

Illinois Tool Works Board Of Directors Approves Quarterly Dividend Rate Increase From $1.50 To $1.61 Per Share

AngloGold Ashanti shares are trading higher after the company reported better-than-expected Q2 financial results.

Church &amp; Dwight Company, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>), on Friday, reported second-quarter results with adjusted earnings per share of 94 cents. The household products maker beat the analyst <a href="https://www.benzinga.com/pressreleases/25/08/b46788730/church-dwight-reports-q2-2025-results" target="_blank" rel="noreferrer noopener">consensus estimate of 85 cents.</a>
Quarterly sales of $1.51 billion outpaced the Street view of $1.48 billion.
Net sales declined 0.3%, with domestic sales down 1.4%, international sales up 5.3%, and SPD segment down 3.0%.
Consumer Domestic net sales totaled $1.154 billion, down 1.4%. Consumer International net sales rose 5.3% to $277.6 million. Specialty Products net sales declined 3.0% to $74.6 million, reflecting the 2024 exit of the Megalac and food safety businesses.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/earnings/25/08/46790713/chevron-achieves-record-production-sees-future-growth-after-hess-deal" rel="noreferrer noopener">Chevron Achieves Record Production, Sees Future Growth After Hess Deal</a>
Adjusted gross margin was 45%, a decrease of 40 basis points with the impact of higher manufacturing costs including tariffs, Zicam/Orajel recall costs, promotional pricing and product mix largely offset by the benefits of our productivity programs and higher margin acquisitions.
Outlook
Church &amp; Dwight reaffirmed its FY25 adjusted earnings per share guidance at $3.44–$3.51, aligning with consensus estimates of approximately $3.48.
For the third quarter, the firm expects reported and organic sales growth of approximately 1%-2%, adjusted gross margin contraction of approximately 100 basis points, primarily from inflation and tariff costs, the lower margins of the exited businesses and increased investments in marketing.
The firm expects adjusted EPS of 72 cents per share, a decrease of 9% versus last year&#8217;s adjusted third-quarter EPS
&#8220;We still expect 2025 capital expenditures of approximately $130 million. We now expect other expense for 2025 to be approximately $65 million,&#8221; CEO Rick Dierker added.
Price Action: CHD shares are trading slightly higher by 0.14% to $93.90 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/08/46791008/bitcoin-plummets-to-115000-ethereum-xrp-dogecoin-follow-lower" target="_blank" rel="noreferrer noopener">Bitcoin Plummets To $115,000, Ethereum, XRP, Dogecoin Follow Lower</a></li>
</ul>
Image: Shutterstock

Earnings

Equities

Guidance

Church & Dwight Tops Q2 Estimates Despite Orajel Recall Costs

Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported better-than-expected second-quarter financial <a href="https://www.benzinga.com/quote/BIO/earnings">results on Thursday</a>.
Bio-Rad Laboratories reported quarterly earnings of $2.61 per share which beat the analyst consensus estimate of $1.76 per share. The company reported quarterly sales of $651.600 million which beat the analyst consensus estimate of $615.110 million.
Bio-Rad Laboratories narrowed its FY2025 sales guidance from $2.541 billion-$2.606 billion to $2.567 billion-$2.593 billion.
Norman Schwartz, Bio-Rad&#8217;s Chairman and Chief Executive Officer, said, &#8220;In a highly dynamic environment, we delivered solid quarterly results, both in terms of revenue and operating margin, through focused execution and careful expense management. We also completed the acquisition of droplet digital PCR developer Stilla Technologies, effectively expanding our Droplet Digital&#x2122; PCR offering with the recent launch of our QX Continuum&#x2122; system complemented by the QX700&#x2122; series of acquired instruments.&#8221;
Bio-Rad Laboratories shares gained 19.5% to trade at $289.03 on Friday.
These analysts made changes to their price targets on Bio-Rad Laboratories following earnings announcement.
<ul class="wp-block-list">
<li>Wells Fargo analyst Brandon Couillard maintained Bio-Rad Laboratories with an Equal-Weight rating and raised the price target from $245 to $265.</li>
<li>RBC Capital analyst Conor McNamara maintained the stock with an Outperform rating and raised the price target from $387 to $409.</li>
</ul>
Considering buying BIO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01112849/image-13-1024x573.png" alt="" class="wp-image-1011112" style="width:647px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01112849/image-13-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01112849/image-13-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01112849/image-13-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/08/01112849/image-13.png 1111w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/news/25/08/46792424/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields-4"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/08/46792424/wall-streets-most-accurate-analysts-weigh-in-on-3-health-care-stocks-with-over-3-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo via Shutterstock

Bio-Rad Laboratories Analysts Raise Their Forecasts After Better-Than-Expected Q2 Earnings

AMETEK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AME#NYSE">AME</a>) has outperformed the market over the past 15 years by 3.58% on an annualized basis producing an average annual return of 15.62%. Currently, AMETEK has a market capitalization of $41.63 billion. 
Buying $1000 In AME: If an investor had bought $1000 of AME stock 15 years ago, it would be worth $8,926.29 today based on a price of $180.43 for AME at the time of writing.
<h3>AMETEK's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1754062217_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In AMETEK 15 Years Ago Would Be Worth This Much Today

RBC Capital analyst Andrew Wong maintains Cameco (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCO#TSX">CCO</a>) with a Outperform and raises the price target from C$100 to C$110.

TSX:CCO

RBC Capital Maintains Outperform on Cameco, Raises Price Target to C$110

Canaccord Genuity analyst William Plovanic maintains iRhythm Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) with a Buy and raises the price target from $139 to $170.

IRTC

Canaccord Genuity Maintains Buy on iRhythm Technologies, Raises Price Target to $170

Contracts

Global

During Conf Call, Chevron CEO Says This Month There Will Be A Limited Amount Of Oil That Will Begin Flowing To The U.S. From The Venezuela Operations; Company Does Not Expect Flows From Venezuela Will Have A Material Impact On Q3 Results

RBC Capital analyst Andrew Wong maintains Cameco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCJ#NYSE">CCJ</a>) with a Outperform and raises the price target from $100 to $110.

RBC Capital Maintains Outperform on Cameco, Raises Price Target to $110

Canaccord Genuity analyst Kyle Mikson maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Hold and raises the price target from $99 to $105.

ILMN

Canaccord Genuity Maintains Hold on Illumina, Raises Price Target to $105

RBC Capital analyst Brian Abrahams maintains Biogen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) with a Outperform and raises the price target from $208 to $219.

BIIB

RBC Capital Maintains Outperform on Biogen, Raises Price Target to $219

Canaccord Genuity analyst David Hynes maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and maintains $40 price target.

FIVN

Canaccord Genuity Maintains Buy on Five9, Maintains $40 Price Target

Press Releases

Webuy Global Ltd. Reports FY2024 Results and Achieves First-Ever Quarterly Profit

Webuy Global Ltd. (Nasdaq: WBUY) Reinstated Listing on Nasdaq Capital Market and Returns to Profitability with Strong First Quarter Growth in Travel

Webuy Global Ltd. Appoints Award-Winning Corporate Leader Heng Wee Koon as Independent Director

Webuy Global Ltd. Named One of Asia-Pacific's Fastest-Growing Companies by Financial Times

Webuy Global Ltd. and CTG MICE Service Company Limited., a Subsidiary of China Tourism Group, Sign Landmark Agreement to Boost Inbound Tourism to China

Webuy Global Ltd Integrates Coinbase to Accept Stablecoin Payments - Leading the Way in Travel Technology and Digital Payments

Synergy CHC Corp. (NASDAQ: SNYR) Secures Distribution Wins for FOCUSfactor® Supplements and Functional Beverages – More Stocks Inside

WEBUY GLOBAL LTD. Launches Groundbreaking AI Travel Assistant Device Powered by DeepSeek V3 Model and Espressif's ESP32-C

WEBUY GLOBAL LTD. Partners with Victory Securities to Pioneer Stablecoin Adoption

WEBUY GLOBAL LTD Announces Pricing of Follow-on Offering

AMZN

ARTL

BMNR

COST

IPDN

PLUG

PNPNF

SNYR

TSXV:PNPN

Albertsons Companies, Inc. Class A Common Stock

Albertsons Companies

Maplebear

Caseys General Stores, Inc. - Common Stock

Casey's General Stores

Chanson International Holding - Class A Ordinary Shares

Chanson International

Dingdong (Cayman) Limited American Depositary Shares (each two representing three Ordinary Shares)

Comments

Webuy Global

Webuy Global (WBUY) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL